JAK-STAT6 Pathway Inhibitors Block Eotaxin-3 Secretion by Epithelial Cells and Fibroblasts from Esophageal Eosinophilia Patients: Promising Agents to Improve Inflammation and Prevent Fibrosis in EoE-Reference-Cited by-同舟云学术

JAK-STAT6 Pathway Inhibitors Block Eotaxin-3 Secretion by Epithelial Cells and Fibroblasts from Esophageal Eosinophilia Patients: Promising Agents to Improve Inflammation and Prevent Fibrosis in EoE

Published:2016-06-16 Issue:6 Volume:11 Page:e0157376
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Cheng Edaire,Zhang Xi,Wilson Kathleen S.,Wang David H.,Park Jason Y.,Huo Xiaofang,Yu Chunhua,Zhang Qiuyang,Spechler Stuart J.,Souza Rhonda F.

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

National Institutes of Health

North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

American Gastroenterological Association (US)

U.S. Department of Veterans Affairs (US)

National Institute of Diabetes and Digestive and Kidney Diseases (US)

National Institutes of Health (US)

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference41 articles.

1. Eosinophilic esophagitis: updated consensus recommendations for children and adults;CA Liacouras;J Allergy Clin Immunol,2011

2. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD;E Cheng;Gut,2013

3. Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells;X Zhang;PLoS One,2012

4. T-helper 2 cytokines, transforming growth factor beta1, and eosinophil products induce fibrogenesis and alter muscle motility in patients with eosinophilic esophagitis;F Rieder;Gastroenterology,2014

5. Impact of Diagnostic Delay and Other Risk Factors on Eosinophilic Esophagitis Phenotype and Esophageal Diameter;S Lipka;J Clin Gastroenterol,2015

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proton pump inhibitor effect on esophageal protein signature of eosinophilic esophagitis, prediction, and evaluation of treatment response;Allergy;2024-08-02

2. Eosinophils, Eosinophilic Gastrointestinal Diseases, and Inflammatory Bowel Disease: A Critical Review;Journal of Clinical Medicine;2024-07-14

3. Effect of benralizumab on histopathology and inflammatory signatures in a clinical cohort of eosinophilic esophagitis;Diseases of the Esophagus;2024-07-11

4. Development and dysfunction of structural cells in eosinophilic esophagitis;Journal of Allergy and Clinical Immunology;2024-06

5. Pharmacologic Management of Eosinophilic Esophagitis;Immunology and Allergy Clinics of North America;2024-05